RCUS Q1 2025 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$28M-80.7% YoY

Gross Profit

$28M100.0% margin

Operating Income

-$122M-435.7% margin

Net Income

-$112M-400.0% margin

EPS (Diluted)

$-1.14

QoQ Revenue Growth

+7.7%

Cash Flow

Operating Cash Flow

-$132M

Free Cash Flow

-$133M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$625M

Stockholders' Equity

$531M

Cash & Equivalents

$192M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$145M	-80.7%
Gross Profit	$28M	$145M	-80.7%
Operating Income	-$122M	-$16M	-662.5%
Net Income	-$112M	-$4M	-2700.0%

Revenue Segments

License and Development Services Revenue

$20M71%

Other Collaboration Revenue

$8M29%